- Home
- RC vs XNCR Comparison
RC vs XNCR Comparison
Compare RC & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RC
- XNCR
- Stock Information
- Founded
- RC 2007
- XNCR 1997
- Country
- RC United States
- XNCR United States
- Employees
- RC N/A
- XNCR N/A
- Industry
- RC Real Estate Investment Trusts
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- RC Real Estate
- XNCR Health Care
- Exchange
- RC Nasdaq
- XNCR Nasdaq
- Market Cap
- RC 1.2B
- XNCR 1.3B
- IPO Year
- RC N/A
- XNCR 2013
- Fundamental
- Price
- RC $6.73
- XNCR $15.74
- Analyst Decision
- RC Hold
- XNCR Strong Buy
- Analyst Count
- RC 9
- XNCR 8
- Target Price
- RC $28.75
- XNCR $34.63
- AVG Volume (30 Days)
- RC 2.0M
- XNCR 455.5K
- Earning Date
- RC 03-03-2025
- XNCR 03-04-2025
- Dividend Yield
- RC 14.88%
- XNCR N/A
- EPS Growth
- RC N/A
- XNCR N/A
- EPS
- RC N/A
- XNCR N/A
- Revenue
- RC $140,359,000.00
- XNCR $85,164,000.00
- Revenue This Year
- RC N/A
- XNCR N/A
- Revenue Next Year
- RC $17.82
- XNCR $80.86
- P/E Ratio
- RC N/A
- XNCR N/A
- Revenue Growth
- RC N/A
- XNCR N/A
- 52 Week Low
- RC $6.39
- XNCR $15.31
- 52 Week High
- RC $9.54
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- RC 47.72
- XNCR 21.76
- Support Level
- RC $6.55
- XNCR $15.53
- Resistance Level
- RC $6.79
- XNCR $16.69
- Average True Range (ATR)
- RC 0.17
- XNCR 0.76
- MACD
- RC 0.03
- XNCR 0.04
- Stochastic Oscillator
- RC 53.12
- XNCR 9.57
About RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.